Your browser version is outdated. We recommend that you update your browser to the latest version.

Development 

We have Worldwide exclusive rights to a novel TLR7 agonist that is a potent stimulator of the innate immune system. The TLR7 agonist has been GMP produced and shown good scale-up and stability properties.

 

Clinical development

We will initiate a clinical phase I study in patients with metastatic cancer, and extent into a phase IIA in combination treatment with existing therapies.